The DOI matches its Crossref record.
Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
Abstract
3508 Background: Cetuximab (Cetux), a monoclonal antibody (mab) that targets the epidermal growth factor receptor (EGFR), has shown antitumor activity both alone and in combination with irinotecan (IRI) in IRI-refractory colorectal cancer (CRC). Bevacizumab (Bev), a mab against vascular endothelial growth factor (VEGF), improved the response rate, PFS, and overall survival in CRC patients treated with first line IFL. We evaluated the safety and efficacy of concurrent administration of these two monoclonal antibodies in patients with metastatic CRC. Methods: This is a randomized phase II study in patients with IRI-refractory CRC. All patients were naive to both bev and cetux. EGFR expression was not required for study entry. Arm A received IRI at the same dose and schedule as last received prior to study, plus Cetux 400 mg/m2 loading dose, then weekly at 250 mg/m2, plus Bev 5 mg/kg given every other week. Arm B received the same Cetux and Bev as arm A, but without IRI. Results: 76 patients have been randomized, 75 of whom received treatment. Median age is 60 (range 25–86). Median number of prior regimens is 3 (range 1–7). Median performance status is ECOG 1 (0–1). Interim toxicity data have been previously presented (ASCO GI Symposium, 1/05). No toxicities were encountered that would not have been expected from the single agents alone. As of 12/04, the median time to tumor progression (TTP) for arm A (Cetux/Bev/IRI) is 5.8 months, with 16 patients currently on treatment. For Arm B (Cetux/Bev) the median TTP was 4.0 months. Response data are shown in the table. Conclusions: The combination of Cetux/Bev, alone or with IRI, is tolerable. The response rates and TTP seen with the addition of Bev to either Cetux or Cetux/IRI appear favorable compared to historical controls of Cetux or Cetux/IRI without Bev. Studies of Cetux/Bev in conjunction with front line combination chemotherapy regimens are warranted and have now been initiated. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Access, Genentech, Pfizer, Roche, Sanofi, Taiho Bristol-Meyers Squibb
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
Labianca, R., Beretta, G. D., Kildani, B., Milesi, L., Merlin, F., Mosconi, S., Pessi, M. A., Prochilo, T., Quadri, A., Gatta, G., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.01.010 · Cited by 409
Metadata
- Authors
- Saltz, L. B., Lenz, H.-J., Hochster, H., Wadler, S., Hoff, P., Kemeny, N., Hollywood, E., Gonen, M., Wetherbee, S., & Chen, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06
- Volume
- 23
- Issue
- 16_suppl
- Pages
- 3508-3508
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2476532096
- Cited by
- 183
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. https://app.cochat.ai/papers/10.1200/jco.2005.23.16_suppl.3508
- The paper
- Saltz, L. B., Lenz, H.-J., Hochster, H., Wadler, S., Hoff, P., Kemeny, N., Hollywood, E., Gonen, M., Wetherbee, S., & Chen, H. (2005). Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.23.16_suppl.3508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.